Melasma treatment with a 1064 nm, picosecond‐domain laser with a fractionated multibeam lens array
Lasers in Surgery and Medicine · 2023-11 · 55 (9) · 801-808
DOI: 10.1002/lsm.23723 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lasers in Surgery and Medicine, online erschienen am 05.09.2023. Verfasst von Eric F Bernstein und 2 weiteren Autor:innen. Beteiligte Einrichtung: Main Line Center for Laser Surgery, Ardmore, Pennsylvania, USA. Hauptthemen laut MEDLINE: Lasers, Solid-State, Melanosis, Low-Level Light Therapy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Objectives Picosecond‐domain lasers have been fitted with fractionated optics for dermal remodeling. This study evaluates the safety and efficacy of a multiwavelength picosecond‐domain laser, using a 1064 nm multibeam lens array, for improving the appearance of melasma. Study Design/Materials and Methods Twenty adults with a clinical diagnosis of melasma were enrolled and received 4 monthly 1064‐nm, 450 ps laser treatments delivered with a 10 × 10 fractional array of 150 µm microbeams. Cosmetic units with melasma were treated with fluences ranging from 1.7 to 2.9 mJ/microbeam with a repetition rate of 6 Hz. Treatment effect was evaluation of digital images by dermatologists blinded as to the treatment conditions, comparing baseline and 3‐ and 8‐month post‐treatment images. Modified melasma area and severity index (mMASI) scores were determined by the study investigator based on clinical photography. Subject self‐assessment of treatment effects was also recorded.
Results
Blinded reviewers correctly identified the post‐treatment image in 16 of the 20 image sets (80%). Ratings demonstrated statistically significant ( p < 0.001) improvement on an 11‐point scale at both the 3‐ and 8‐month timepoints for a mean improvement of 3.7 point (range −8 to 10) or 37% improvement at the 3‐month follow‐up, and 2.7 (range −8 to 9) or 27% at the 8‐month follow‐up for all subjects. The average mMASI score showed highly significant reduction at both the 3‐ and 8‐month follow‐ups compared to baseline ( p < 0.01). Most subjects (90%) were satisfied with the treatment outcome in melasma at both follow‐ups, which is consistent with the treatment outcome and mMASI scores.
Conclusion
The fractionated, picosecond‐domain, 1064 nm laser is safe and effective for improving melasma and should be considered as an adjunct to topical treatment regimens and sun‐protection for management of melasma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Main Line Center for Laser Surgery, Ardmore, Pennsylvania, USA.
- SUNY Downstate Health Sciences University, New York, USA.
ORCID-Profile: Eric F Bernstein
Zitieren
APA
Bernstein, E. F., Basilavecchio, L. D., & Wang, J. (2023). Melasma treatment with a 1064 nm, picosecond‐domain laser with a fractionated multibeam lens array. Lasers in Surgery and Medicine, 55(9), 801-808. https://doi.org/10.1002/lsm.23723
Vancouver
Bernstein EF, Basilavecchio LD, Wang J. Melasma treatment with a 1064 nm, picosecond‐domain laser with a fractionated multibeam lens array. Lasers in Surgery and Medicine. 2023;55(9):801-808. doi:10.1002/lsm.23723
BibTeX
@article{Bernstein2023,
author = {Bernstein, Eric F and Basilavecchio, Lisa D and Wang, Jenny},
title = {Melasma treatment with a 1064 nm, picosecond‐domain laser with a fractionated multibeam lens array},
journal = {Lasers in Surgery and Medicine},
year = {2023},
volume = {55},
number = {9},
pages = {801--808},
doi = {10.1002/lsm.23723}
}
EUVIMED